01513.HK
Livzon Pharmaceutical Group Inc.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 20.38
+0.79%Year over year
Reported trailing growth
- Revenue
- -9.4%
- EBITDA
- -12.8%
- EBIT
- -28.1%
- EPS
- -21.2%
- Free cash flow
- +73.7%
- Operating cash flow
- +95.6%
Forward estimates
Based on analyst estimates
- Revenue
- -50.6%
- EBITDA
- -44.0%
- EPS
- -46.1%
Three-year CAGR
- Revenue
- -1.6%
- EBITDA
- +0.2%
- EBIT
- +7.8%
- Net income
- +1.9%
- EPS
- +3.6%
- Free cash flow
- +11.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026